1. Home
  2. MKTW vs XLO Comparison

MKTW vs XLO Comparison

Compare MKTW & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MarketWise Inc.

MKTW

MarketWise Inc.

N/A

Current Price

$18.50

Market Cap

54.6M

Sector

Technology

ML Signal

N/A

XLO

Xilio Therapeutics Inc.

HOLD

Current Price

$8.95

Market Cap

56.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MKTW
XLO
Founded
1999
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.6M
56.9M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
MKTW
XLO
Price
$18.50
$8.95
Analyst Decision
Hold
Buy
Analyst Count
1
1
Target Price
$20.00
$28.00
AVG Volume (30 Days)
15.9K
9.5K
Earning Date
05-07-2026
05-14-2026
Dividend Yield
10.20%
N/A
EPS Growth
1183.33
N/A
EPS
N/A
N/A
Revenue
$512,403,000.00
$43,766,000.00
Revenue This Year
$1.52
N/A
Revenue Next Year
$4.55
$168.77
P/E Ratio
N/A
N/A
Revenue Growth
N/A
589.88
52 Week Low
$13.49
$0.46
52 Week High
$22.83
$9.90

Technical Indicators

Market Signals
Indicator
MKTW
XLO
Relative Strength Index (RSI) 49.12 47.21
Support Level $16.22 $8.52
Resistance Level $21.40 $9.22
Average True Range (ATR) 0.56 0.29
MACD 0.05 -0.03
Stochastic Oscillator 74.16 53.33

Price Performance

Historical Comparison
MKTW
XLO

About MKTW MarketWise Inc.

Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms, including mobile, desktop, and tablets.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Share on Social Networks: